Search Results
Aug 03, 2026, 08:55 ET Guidewire Introduces Qusar Release to Help Insurers Build and Control AI Agents
P&C insurers.We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest partner community in P&C, where customers can access hundreds of applications
More news about: Guidewire Software
Aug 03, 2026, 08:55 ET Guidewire Introduces Qusar Release to Help Insurers Build and Control AI Agents
P&C insurers.We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest partner community in P&C, where customers can access hundreds of applications
More news about: Guidewire Software
Aug 03, 2026, 08:17 ET Genezen and the Raiden Science Foundation Announce Partnership for AAV9 Gene Replacement Therapy for UBA5 Clinical Trial
gene replacement therapy for UBA5 disorder. This partnership marks a major milestone for RSF, moving its UBA5 gene therapy program from four years of R&D into clinical manufacturing and one step closer to the first-in-human clinical trial for this devastating disorder.
More news about: Genezen
Aug 03, 2026, 08:04 ET Diebold Nixdorf Recognized as an Android™ Enterprise Gold Partner
www.youtube.com/dieboldnixdorfAndroid is a trademark of Google LLC.DN-R
More news about: Diebold Nixdorf, Incorporated
Aug 03, 2026, 08:00 ET Broadcom Inc. to Announce Third Quarter Fiscal Year 2026 Financial Results on Wednesday, September 2, 2026
develops, and supplies semiconductors and infrastructure software for global organizations' complex, mission-critical needs. Broadcom combines long-term R&D investment with superb execution to deliver the best technology, at scale. Broadcom is a Delaware corporation headquartered in Palo Alto, CA. For more
More news about: Broadcom Inc.
Aug 03, 2026, 08:00 ET cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease
Graham Heap, MD, PhD joins as President, Research and Development (R&D), with responsibility for leading all the Company's research and development activities. Ezequiel Neimark, MD joins as Head of Clinical Development
More news about: cAMPfield Therapeutics
Aug 03, 2026, 08:00 ET Lipocine Appoints Michael J. Grissinger to Board of Directors
Johnson, Mr. Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was also a member of the Immunology R&D/Commercial leadership team for Johnson & Johnson's Worldwide Immunology Franchise. Prior to Johnson & Johnson, Mr. Grissinger spent 12 years at
More news about: Lipocine Inc.
Aug 03, 2026, 08:00 ET FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant
More news about: Acurx Pharmaceuticals, Inc.
Aug 03, 2026, 07:00 ET Compugen Reports Second Quarter 2026 Results
2025 reflect the recognition of portions of both the upfront payment and the IND milestone payment from the license agreement with Gilead.R&D expenses for the second quarter of 2026 were approximately $6.3 million, compared to approximately $5.6 million in the second quarter
More news about: Compugen Ltd.
Aug 03, 2026, 06:55 ET 歌禮宣佈其GLP-1口服小分子ASC30啟動全球III期臨床研究，並公佈其同類首創口服小分子GLP-1/GIP/胰澱素固定劑量復方制劑的積極臨床前數據
復方制劑；ASC39，一款與eloralintide類似、強效且對胰澱素具有選擇性的每日一次口服小分子胰澱素受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FD），一款每月一次皮下注射四靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35 FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered
More news about: Ascletis Pharma Inc.
Aug 03, 2026, 06:00 ET Varda Announces Biopharma Leader Mikael Dolsten will Join Board as Space-Based Pharmaceutical Manufacturing Accelerates
pharmaceutical leader Mikael Dolsten to its board of directors. Dolsten is one of biopharma's most accomplished R&D leaders, having served for 16 years as Chief Scientific Officer and President of Pfizer R&D, where he oversaw the approval of more than 36 medicines and vaccines and advanced more than 150 drug
More news about: Varda Space Industries Inc.
Aug 03, 2026, 06:00 ET CNA FINANCIAL ANNOUNCES SECOND QUARTER 2026 NET INCOME OF $1.18 PER SHARE AND CORE INCOME OF $1.19 PER SHARE
section. Remarks will include commentary from the Company's Chairman and Chief Executive Officer, Douglas M. Worman, and Chief Financial Officer, Scott R. Lindquist. An earnings presentation and financial supplement information related to the results will also be posted and available on the CNA website.Definition
More news about: CNA Financial
Aug 03, 2026, 05:49 ET WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model
dividend.About WuXi AppTecWuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end
More news about: WuXi AppTec
Aug 03, 2026, 05:00 ET HIZENERGY dołącza do światowej czołówki, trafiając na listę BloombergNEF Tier 1
sierpnia 2026 r. /PRNewswire/ -- 31 lipca 2026 r. BloombergNEF (BNEF), wiodący na świecie ośrodek badawczy specjalizujący się w sektorze energetycznym, opublikował listę producentów magazynów energii o wysokich parametrach technicznych (Tier 1) na III kwartał 2026 r. Założona zaledwie
More news about: HIZENERGY
Aug 03, 2026, 05:00 ET Hisense wprowadza na rynek PX4 Pro i przenosi profesjonalne doświadczenia kinowe do domu
QINGDAO, Chiny, 3 sierpnia 2026 r. /PRNewswire/ -- Hisense, czołowa światowa marka elektroniki użytkowej i sprzętu AGD, zaprezentowała dziś model PX4 Pro - nowy projektor TriChroma Laser Cinema, zaprojektowany z myślą o tym,
More news about: Hisense
Aug 03, 2026, 04:59 ET Invenio Imaging Announces Completion of Enrollment in Landmark Study of AI-Based Image Analysis for Lung Cancer
States.Research reported in this press release is supported by the National Cancer Institute of the National Institutes of Health under Award Number 1R44CA281581-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.CONTACT:
More news about: Invenio Imaging
Aug 03, 2026, 04:30 ET ADOIT 20.0 wprowadza dynamiczne wyszukiwanie, konfigurowalne kokpity oraz ocenę zgodności aplikacji
zarządzanie architekturą w całej organizacji.WARSZAWA, 3 sierpnia 2026 r. /PRNewswire/ --
More news about: BOC Products & Services AG
Aug 03, 2026, 03:09 ET MediSun Energy and JA Sign Ecosystem MoU at DRT SHOW Chengdu to Build Zero-Carbon Water Systems for Island and Coastal Environments
Asia.About JAJA is a global leader in high-performance photovoltaic (PV) products, integrated green energy systems, and solar technology R&D. Through its JAx industry solutions platform, JA collaborates with industry-leading partners across cultural tourism, agriculture, and industrial sectors
More news about: MediSun Planet Pte Ltd
Aug 03, 2026, 02:58 ET Share buybacks in Ericsson during the period July 27 - July 31, 2026
https://news.cision.com/ericsson/r/share-buybacks-in-ericsson-during-the-period-july-27---july-31--2026,c4379208The following files are available for download:
More news about: Ericsson
Aug 03, 2026, 02:51 ET Share buybacks in Ericsson during the period July 27 - July 31, 2026
https://news.cision.com/ericsson/r/share-buybacks-in-ericsson-during-the-period-july-27---july-31--2026,c4379208The following files are available for download:
More news about: Ericsson
Aug 03, 2026, 02:20 ET ASSA ABLOY to acquire Gunnebo Entrance Control
https://news.cision.com/assa-abloy/r/assa-abloy-to-acquire-gunnebo-entrance-control,c4379298The following files are available for download:
More news about: ASSA ABLOY
Aug 03, 2026, 02:16 ET ASSA ABLOY to acquire Gunnebo Entrance Control
https://news.cision.com/assa-abloy/r/assa-abloy-to-acquire-gunnebo-entrance-control,c4379298The following files are available for download:
More news about: ASSA ABLOY
Aug 03, 2026, 01:56 ET IMPACT Therapeutics signe un accord de licence exclusif avec Pharmanovia concernant le sénaparib en Europe, au Moyen-Orient et en Afrique du Nord, ainsi qu'en Australie et en Nouvelle-Zélande
inhibiteur de WEE1 (IMP7068) et de nombreux autres inhibiteurs ciblant la létalité synthétique.Notre croissance continue repose sur une plateforme de R & D intégrée qui favorise l'innovation tant dans le domaine des petites molécules que dans celui des modalités émergentes, notamment les conjugués
More news about: IMPACT Therapeutics
Aug 03, 2026, 01:33 ET TOMY宣佈tomica終極多層停車庫將於2026年9月起在10個亞洲市場上市 首個官方粉絲社群定於10月上線
專為成年多美卡(TOMICA)粉絲設計：搭載進階配置，支持遙控進出車、機械質感且流暢優雅的運轉動作、360度旋轉電梯式展示台、定制燈光、靜音運行設計、啞光質感外觀以及精緻印刷圖案。套裝內含一台tomica PREMIUM系列Nissan GT-R NISMO特別版壓鑄迷你玩具車。附贈的Nissan GT-R NISMO特別版小車：
More news about: TOMY Company, Ltd.